|Daily Range||$29.51 - $30.86|
|52-Week Range||$23.61 - $48.50|
|Dividend (Yield)||$0.00 (0.0%)|
|Average Daily Volume||180,052|
|Current FY EPS||-$1.34|
CONTROLADORA VUELA SPON ADR REPR 10 CPOS (XLRN) Description
CONTROLADORA VUELA SPON ADR REPR 10 CPOS Website: http://www.acceleronpharma.com/
News & Commentary
Acceleron Pharma, bluebird bio, and Sarepta Therapeutics are three rare disease specialists with upcoming catalysts that could propel their shares higher.
Acceleron Reports Publication in Cancer Research Dalantercept Prevents Metastases in Preclinical Studies of Breast Cancer
Acceleron Announces New Luspatercept Phase 2 Clinical Results at the 20th Congress of the European Hematology Association
Despite three decades of intense work leading to over 400 new treatments, we have barely made a dent in the vast unmet medical need for rare diseases. Here is a look at three striking examples underscoring the point.
The Zacks Analyst Blog Highlights: Eleven Biotherapeutics, bluebird, Agios, Acceleron and Achillion - Press Releases